SLC5A2 and hepatocellular carcinoma: After propensity score matching and adjustments, SGLT2-inhibitor use was associated with a significantly lower risk of HCC (HR, 0.42; 95% CI, 0.28–0.79) compared to DPP4i, with this protective effect also observed in patients with cirrhosis, advanced fibrosis, HBV, and HCV infections.